Analyst firms · BofA Securities · TDOC

BofA Securities TDOC price target and rating history

Teladoc Health Inc. (TDOC) · Health Care

BofA Securities rates Teladoc Health Inc. (TDOC) Buy with a $7 price target, as of its latest action on Feb 26, 2026. It has published 4 rating actions on TDOC since October 2021, including 1 upgrade and 0 downgrades. Across 3 firms with a TDOC price target in the last 12 months, the median target is $8.50. BofA Securities's $7 is 18% below that.

Current rating
Buy
Price target
$7
Median target, all firms
$8.50
Actions on TDOC
4

BofA Securities price target on TDOC

$80$44$720222023202420252026
BofA Securities price target on TDOC, each point a stated target, October 2021 to February 2026. Targets before February 2022 (divided by 2) are adjusted for a stock split, going by the prior target BofA Securities restated.

Every BofA Securities rating on TDOC

How other firms rate TDOC

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Argus ResearchSellNov 2, 2026
Deutsche BankBuy$11Mar 10, 2026
BofA SecuritiesBuy$7Feb 26, 2026
BarclaysEqual Weight$8.50Dec 9, 2025

Questions about BofA Securities and TDOC

What is BofA Securities's price target for TDOC?
BofA Securities's latest stated price target for Teladoc Health Inc. (TDOC) is $7, from its action on Feb 26, 2026.
What is BofA Securities's rating on TDOC?
BofA Securities rates TDOC Buy, a bullish rating, as of Feb 26, 2026.
When did BofA Securities last change its view on TDOC?
On Feb 26, 2026, BofA Securities upgrades to Buy from Neutral, price target $7.
How does BofA Securities's TDOC target compare with other analysts?
Across 3 firms with a TDOC price target in the last 12 months, the median target is $8.50. BofA Securities's $7 is 18% below that.

More TDOC rating histories

All BofA Securities ratingsTDOC news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.